Premium
Wnt/β‐catenin signaling plays a key role in the development of spondyloarthritis
Author(s) -
Xie Wanqing,
Zhou Lijiang,
Li Shan,
Hui Tianqian,
Chen Di
Publication year - 2016
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12968
Subject(s) - ankylosing spondylitis , wnt signaling pathway , sclerostin , medicine , arthritis , psoriatic arthritis , tumor necrosis factor alpha , dkk1 , ankylosis , disease , immunology , cancer research , bioinformatics , signal transduction , biology , surgery , biochemistry
Spondyloarthritis (SpA) is a group of diseases consisting of psoriatic arthritis (PsA), reactive arthritis, arthritis related to inflammatory bowel disease (a subgroup of juvenile idiopathic arthritis), and ankylosing spondylitis (the prototype of SpA). Axial bone formation and the combination of concurrent erosion and new bone formation are specific characteristics of SpA disease. The use of antiproinflammatory cytokines, such as inhibitors of tumor necrosis factor α (TNF‐α), appears to be the greatest advance in the treatment of SpA over the past 20 years. However, TNF‐α blockers do not halt new bone formation. Recent clinical observations and animal studies demonstrate that Wnt signaling proteins and natural Wnt inhibitors, such as DKK1 and sclerostin, are likely to play important roles in the process of ankylosis in SpA, and could potentially serve as therapeutic targets for the treatment of SpA.